NEW YORK (GenomeWeb News) – Life Technologies today announced a worldwide, non-exclusive deal with iPS Academia Japan for its induced pluripotent stem cell patent portfolio.

The agreement grants Life Tech the rights to commercialize a range of products and services designed to create iPS cells and differentiate them into any cell type for drug discovery and pre-clinical research. Life Tech will also be able to provide iPS cell creation, differentiation, and screening services to the scientific community.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.